Priti Patle, Chandrashekhar Tenpe, Sumit Rathod, Durgesh Gautam
Priti Patle1*, Dr. Chandrashekhar Tenpe4, Mr. Sumit Rathod3, Mr. Durgesh Gautam2
1Yashwantrao Bhonsale College of D. Pharmacy, Sawantwadi, Building No. 02, A/P Charathe - Vazarwadi, Sawantwadi, Maharashtra - 416510, India.
2Yashwantrao Bhonsale College of Pharmacy, Sawantwadi, Building No. 02, A/P Charathe - Vazarwadi, Sawantwadi, Maharashtra - 416510, India.
3Institute of Pharmaceutical Education and Research, Wardha (MS) – 442001, India.
4Department of Pharmacy, Government Polytechnic Gadge Nagar, VMV Road Amravati 444603, India.
Volume - 11,
Issue - 3,
Year - 2021
Kynurenic acid is a recognized broad-spectrum antagonist of excitatory amino acid receptors with a particularly high affinity for the glycine co-agonist site of the N-methyl-D-aspartate (NMDA) receptor complex. D- Cycloserine is a NMDA receptor partial agonist which facilitate in an initiation of nicotine withdrawal symptoms and dependence. Thus, the influence of kynurenic acid treatment on the development and expression of nicotine dependence was tested by using the nicotine withdrawal-induced hyperexcitability paradigm. Mice were provided with a nutritionally balanced control liquid diet as the sole nutrient source on day 0; from day 1–4 (nicotine 25µg), from day 5–7 (nicotine, 50ug) and from day 8–10 (nicotine, 100ug) was incorporated into the liquid diet. On day 11, the nicotine liquid diet was replaced with nutritionally balanced control liquid diet, and nicotine withdrawal-induced hyperexcitability signs were recorded. The results revealed that acute administration of kunurenic acid (50 and 100mg/kg, i.p.) dose-dependently attenuated nicotine withdrawal-induced hyperexcitability signs, and these results were comparable to D- Cycloserine (50 and 100mg/kg, i.p.) Further, chronic administration of kunurenic acid (50 and 100mg/kg, i.p.) to the nicotine diet fed mice markedly attenuated the nicotine withdrawal-induced hyperexcitability signs. In conclusion, the results and evidence suggest that kinurenic acid exhibited an inhibitory influence against nicotine withdrawal-induced hyperexcitability signs, which could be mediated through its neuromodulatory action.
Cite this article:
Priti Patle, Chandrashekhar Tenpe, Sumit Rathod, Durgesh Gautam. Effect 1 of NMDA Receptor Agonist and Antagonist on Nicotine withdrawal induced Hyperexcitability in Mice. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(3):205-2. doi: 10.52711/2231-5659.2021.00033
Priti Patle, Chandrashekhar Tenpe, Sumit Rathod, Durgesh Gautam. Effect 1 of NMDA Receptor Agonist and Antagonist on Nicotine withdrawal induced Hyperexcitability in Mice. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(3):205-2. doi: 10.52711/2231-5659.2021.00033 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2021-11-3-5
1. Thakre PP, Tundulwar MR, Chopde CT, et.al; Neurosteroidallopregnanolone attenuates development of nicotine withdrawal behavior in mice. Neuroscience Letters 2013; 541: 144– 149
2. Hughes JR. Measurement of the effects of abstinence from tobacco: a qualitative review, Psychol. Addict. Behav 2007; 21: 27–37.
3. Isola R, Vogelsberg V, Wemlinger TA, Neff NH, Hadjiconstantinou M, Nicotine withdrawal in the mouse, Brain Res.1999. 850: 189–196.
4. Seaton MJ, Vesell ES. Variables affecting nicotine metabolism. PharmacTher 1993; 60: 461-500.
5. Benowitz NL. Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment.The American Journal of Medicine 2008; 121: (4A): S3–S10.
6. Benowitz NL. Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. Annu Rev PharmacolToxicol 2010; 49: 57–71.
7. Kumari V, Postma P., Nicotine use in schizophrenia: The self-medication hypotheses. Neuroscience and Biobehavioral Reviews 2005; 29: 1021–1034
8. Varania AP, Moutinho LM, Calvo M. Ability of baclofen to prevent somatic manifestations and neurochemical changes during nicotine withdrawal. Drug and Alcohol Dependence 2011; 119: 5– 12.
9. Shannon P, Blair H, Jennifer O. Effect of nicotine on ethanol dependence and brain damage. S. Penland/alcohol 2001; 24: 45-54.
10. Leventhala AM, Lee M, Bergen AW. Nicotine dependence as a moderator of genetic inﬂuences on smoking cessation treatment outcome. Drug and Alcohol Dependence.2014; 138: 109–117.
11. Zielinska E, Kuc D, Zgrajka W, Turski WA. Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain—In vitro and ex vivo evidence. Toxicology and Applied Pharmacology 2009; 240: 174–179.
12. Stone TW. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends PharmacolSci 2000; 21: 149–154.
13. Guidetti P, Okuno E, Schwarcz R. Characterization of rat brain kynurenine aminotransferases I and II. J. Neurosci. Res 1997; 50: 457–465.
14. Han Q, Robinson H, Cai T, Tagle DA, Li J. Biochemical and structural properties of mouse kynurenine aminotransferase III. Mol. Cell. Biol 2009;29: 784–793.
15. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001; 21: 7463–7473.
16. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993; 45: 309–379.
17. Khanna JM, Morato GS. D-Cycloserine Enhances Rapid Tolerance to Ethanol Motor Incoordination. Pharmacology Biochemistry and Behavior 1994; 52:3: 609-614.
18. Duncan E, Szilagyi S, Schwartz MP. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophrenia Research 2004; 71: 239– 248.
19. Pitkinen M, Sirvi J, Lahtinen H, Koivisto E, Riekkinen P D-Cycloserine, a partial agonist at the glycine site, enhances the excitability of dentate granule cells in vivo in rats. European Journal of Pharmacology 1993; 253: 125-129.
20. Bhutada P, Mundhada Y, Bansod K, Hiware R, Rathod S. Berberine Protects C57BL/6J Mice against Ethanol Withdrawal-induced Hyperexcitability. Phytotherapy research phytother res 2011; 25: 302–307
21. Umathe SN, Bhutada PS, Jain NS, Shukla NR. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like eﬀect of corticotrophin-releasing hormone in mice. Neuropeptides 2008; 42: 399–410.
22. Hong LZ, Cheng PW, Cheng WH., Involvement of NMDA Receptors in Nicotine-Mediated Central Control of Hypotensive Effects. Chinese Journal of Physiology 2011; 55(5): 337-345.
23. Kaminski RM, Zielinska E, Dekundy A, Luijtelaar GV, Waldemar A. Turski.” Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy”. Pol. J. Pharmacol 2003; 55,741–746.
24. Li X, Semenov S, D’Souza MS. Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology 2013; 76: 554-565.
25. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine & Tobacco Research 2000; 2: 19–37.
26. Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. European Journal of Neuroscience 2009; 29: 529–538.
27. Richter A, Lscher W, Baran H, Gramer M Increased levels of kynurenic acid in brains of genetically dystonic hamsters. Developmental Brain Research 1995; 92: 111 – 116.